![](/img/cover-not-exists.png)
1282PResponder analysis based on patient-reported outcomes (PROs) and clinical endpoints (CEPs) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab
D'Angelo, S P, Fofana, F, Schlichting, M, Henry-Szatkowski, M, Hennessy, M, Bharmal, MVolume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy289.038
Date:
October, 2018
File:
PDF, 90 KB
english, 2018